Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients ...

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -

Related Keywords

Milan ,Lombardia ,Italy ,United States ,Wildon Farwell ,Joshua Brumm ,Stacy Nartker ,Valeriaa Sansone ,Amy Reilly ,Perry Shieh ,Los Angeles ,David Geffen School Of Medicine ,European Medicines Agency ,University Of Milan ,Exchange Commission ,Dyne Therapeutics Inc ,Linkedin ,Drug Administration ,Myotonic Dystrophy Health Index ,Facebook ,Gene Panel ,Nasdaq ,Clinical Center Ne ,Dose Dependent Splicing Correction ,Muscle Delivery ,Evaluable Patients ,Cohort Treated ,Demonstrated Consistent Splicing Correction ,Mean Improvement Across ,Lowest Dose ,Mean Dystrophin Expression ,Cohort Administered Monthly ,Greater Than ,Higher Dystrophin Than Reported ,Weekly Administered Current Standard ,Safety Profile ,Supported Dose Escalation ,Enrollment Complete ,Webcast Event Today ,Reported Outcome ,Scientific Director ,Clinical Center ,David Geffen School ,Ronald Reagan ,Myotonic Dystrophy Type ,Duchenne Muscular Dystrophy ,Private Securities Litigation Reform Act ,Region ,